Litigation Details for Intercept Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2020)

Intercept Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2020)

Docket	1:20-cv-01154	Date Filed	2020-08-28
Court	District Court, D. Delaware	Date Terminated	2023-01-25
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,047,117; 10,052,337; 10,174,073; 10,751,349; 10,758,549; 9,238,673
Link to Docket	External link to docket

Details for Intercept Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-08-28				External link to document
2020-08-28	14	Complaint - Amended	expiration of U.S. Patent Nos. 9,238,673 (filed June 17, 2013) (“the ’673 patent”); 10,047,117 (filed Nov. …Paragraph IV Certification of U.S. Patent Nos. 9,238,673; 10,047,117; 10,052,337; and 10,174,073 Concerning… 1. This action for patent infringement, brought pursuant to the patent laws of the United States…20, 2015) (“the ’117 patent”); 10,052,337 (filed Apr. 26, 2016) (“the ’337 patent”); 10,174,073 (filed…25, 2017) (“the ’073 patent”); 10,751,349 (filed Jan. 15, 2019) (“the ’349 patent”); and 10,758,549 (filed	External link to document
2020-08-28	15	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,238,673 B2; 10,047,117 B2; 10,052,… 28 August 2020 1:20-cv-01154 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-08-28	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,238,673 B2; 10,047,117 B2; 10,052,… 28 August 2020 1:20-cv-01154 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for Intercept Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC | 1:20-cv-01154

Last updated: February 25, 2026

Case Overview

Intercept Pharmaceuticals, Inc. filed suit against Amneal Pharmaceuticals LLC in the U.S. District Court for the District of Delaware under case number 1:20-cv-01154. The case primarily concerns patent infringement allegations related to pharmaceutical formulations targeting nonalcoholic steatohepatitis (NASH).

Timeline and Key Proceedings

• Filing Date: May 21, 2020

• Initial Complaint: alleges infringement of U.S. Patent Nos. 10,565,915 and 10,566,358, granted in 2019 and covering specific drug compositions and methods of treatment.

• Amneal's Response: filed an answer on August 4, 2020, denying infringement and asserting invalidity defenses based on prior art.

• Discovery Phase: commenced in late 2020, with both parties exchanging relevant documents and expert disclosures.

• Motions:

  • Intercept filed motions for partial summary judgment arguing infringement of the '915 patent.
  • Amneal filed motions to dismiss under Federal Rule of Civil Procedure 12(b)(6) or, alternatively, for summary judgment of invalidity.

• Trial Schedule: Jointly proposed trial date set for early 2022, with pretrial conferences to follow.

Patent Claims and Allegations

Intercept claims the patents cover a specific combination of bile acid derivatives used in treating NASH:

• The '915 patent claims methods of administering a composition comprising obeticholic acid (OCA) with specific dosing regimens.
• The '358 patent claims pharmaceutical compositions with particular excipients enhancing bioavailability.

Intercept alleges Amneal launched generic versions of the OCA formulation before patent expiration, infringing these claims.

Key Legal Issues

Patent Validity

• Amneal challenges the patents' validity based on prior art references, arguing the claimed invention was obvious and lacked novelty.

Infringement

• Intercept claims Amneal's generic formulations infringe the patents by containing the same active ingredient and using similar dosing methods.

Patent Term and Market Impact

• The patents are set to expire in 2034, providing a 14- to 15-year exclusivity period.
• The case influences market entry strategies for other generic manufacturers in the NASH therapeutic space.

Significant Developments

• In July 2021, the court denied Amneal's motion to dismiss, allowing the case to proceed.
• Intercept's motion for partial summary judgment received approval in March 2022, solidifying the infringement claims for specific aspects of the patent claims.
• The parties are engaging in settlement discussions as of Q2 2022, with trial scheduled for early 2023.

Patent Litigation Trends and Implications

• The case highlights the ongoing patent enforcement efforts by innovator firms in the hepatology treatment space.
• It reflects typical patent challenges faced by generic manufacturers, notably around obviousness and prior art defenses.
• The outcome impacts licensing and market entry strategies for competing firms, especially in high-value pharmaceutical markets like NASH.

Market and Business Implications

• A favorable ruling for Intercept could extend patent protections, delaying generic competition.
• An adverse ruling may facilitate earlier market entry for Amneal and other generics, reducing drug prices and impacting Intercept’s revenue.
• The case underscores the significance of patent fortification and litigation readiness for pharmaceutical innovators.

Conclusion

The litigation tests the strength of Intercept's patent portfolio against generic challenge strategies. Its resolution could influence patent enforcement practices and competitive dynamics in NASH therapeutics.

---

Key Takeaways

• The case revolves around patent rights for NASH treatment formulations containing obeticholic acid.
• Intercept accuses Amneal of infringing patents supporting drug exclusivity through early generic entry.
• Validity challenges based on prior art are central to Amneal's defense.
• Court rulings on infringement and invalidity motions will shape market access for generics.
• The case may set precedents for patent litigation in complex pharmaceutical formulations.

---

FAQs

1. What patents are involved in this case?
The case involves U.S. Patent Nos. 10,565,915 and 10,566,358, granted in 2019, covering formulations and methods of administering obeticholic acid for NASH.

2. What are the main legal defenses used by Amneal?
Amneal challenges patent validity based on obviousness and prior art references, arguing the patents do not meet statutory requirements for novelty and non-obviousness.

3. How does this case impact the market for NASH drugs?
A ruling in favor of Intercept could prolong patent exclusivity, delaying generic entry. A ruling for Amneal could accelerate generic competition, affecting pricing and revenue.

4. When is the trial scheduled?
The trial is scheduled for early 2023, with pretrial activities ongoing as of mid-2022.

5. What is the potential for settlement?
Parties are reportedly engaging in settlement discussions, which could resolve the dispute earlier, though no formal agreement has been announced.

---

References

1. U.S. District Court for the District of Delaware. (2020). Intercept Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC, Case No. 1:20-cv-01154.
2. U.S. Patent and Trademark Office. (2019). Patents Nos. 10,565,915 and 10,566,358.
3. Bloomberg Law. (2022). Litigation Tracker – Pharma Patent Cases.